Clinicians → Coverage & Documentation · Last reviewed August 17, 2026
How to Qualify a Patient for a Nebulizer
A plain-English guide to Medicare's nebulizer coverage — the drug drives the claim: which drug, for which condition, in what monthly quantity, and the duplicate-therapy rules that deny quietly. Based on LCD L33370, Policy Article A52466, and SDR A55426.
Send us three things and we can deliver:
- Chart note naming the drug + the condition it treats — must be a covered pair (see Step 1).
- Standard Written Order covering equipment + drug with quantity per unit of time.
- Diagnosis code — must appear on every claim for equipment, accessories, and drugs.
Fax to (800) 438-2048. We check the diagnosis against the Policy Article's ICD-10 list before billing.
If none of the drugs used with the nebulizer are covered, the compressor, the nebulizer, and all related accessories and supplies are denied. The machine is covered because the drug is covered — not the other way around.
Step 1 — The drug and the condition it treats
Small volume nebulizer (A7003/A7004/A7005) + compressor (E0570) are covered when reasonable and necessary to administer one of these drugs for its covered condition:
Step 2 — The medical record
Send the whole note. What has to be in it:
- Diagnosis that necessitates nebulizer therapy, coded
- Which drug, dose, times per day — drives the monthly quantity we may dispense
- Duration + clinical course of the condition
- Why nebulized vs inhaler, if either could be used
- For thick secretions: character and persistence
- For large volume: tracheostomy / stent / CF / bronchiectasis
- For ensifentrine / PH drugs: the full hemodynamic + treatment-history documentation (see below)
Supplier statements and attestations are not sufficient even when signed. It has to be in your note.
Step 3 — The Standard Written Order (SWO)
We must have a completed SWO before we bill. Six elements:
- Patient name or MBI
- Order date
- Description — "nebulizer compressor" or HCPCS or brand/model
- Quantity to be dispensed
- Treating practitioner name or NPI
- Practitioner signature — stamps not accepted
- Equipment + drug with dose and frequency so monthly quantity can be calculated
- New order if dose / frequency / drug changes
Who may bill the drug: only the entity that actually dispenses it and is licensed to dispense in its state. Practitioners may bill only if enrolled as a DMEPOS supplier with NSC, actually dispensing, and authorized by the state. We will draft it. Fax (800) 438-2048.
The hard part — quantity limits and duplicate-therapy rules
What denies claims in this category is the pharmacy side, quietly — supplies go out, and three months later a claim rejects because the prescription conflicts with a rule nobody read.
| Rule | What gets denied |
|---|---|
| Albuterol + levalbuterol + metaproterenol — only one short-acting beta-agonist at a time | The additional short-acting agent |
| Formoterol + arformoterol — only one long-acting beta-agonist | The additional long-acting agent |
| Revefenacin (LAMA) + short-acting muscarinic ipratropium | Short-acting — ipratropium |
| J7620 combo vial + loose albuterol/levalbuterol/ipratropium | J7611/J7612/J7613/J7614/J7644 billed with J7620 |
Allowed: albuterol/levalbuterol/metaproterenol as rescue alongside formoterol/arformoterol — at the reduced quantities above. If transitioning between agents, tell us — we would rather write a new SWO than watch a claim deny.
Saline is not always separately payable
| Situation | Saline |
|---|---|
| Concentrated drug requiring dilution | Separate saline (A4216/A4218 metered) is separately reimbursed — billed on same claim as drug |
| Unit dose, dilute enough as-is | Denied — not reasonable & necessary |
| Compounded unit dose | Diluent must not be billed separately |
| 500/1000 ml water/saline A4217/A7018 | Denied — only in large volume nebulizer A7007/A7017/E0585 |
Ensifentrine — the most documented drug in the policy
Covered as add-on for COPD only. Standing alone, not reasonable and necessary. Treating practitioner must document item 1 and either 2 or 3:
1. Will continue dual LABA/LAMA or triple LABA/LAMA/ICS maintenance therapy. Say it in the note.
2. Continued exacerbations despite that therapy within 12 months, by either:
- (a) ≥1 exacerbation leading to hospitalization, ER visit, or new systemic glucocorticoids/antibiotics
- (b) ≥3 of 5 clinical parameters during one exacerbation:
| Parameter | Threshold |
|---|---|
| Dyspnea VAS (0–10) | >5 |
| Respiratory rate | >24 /min |
| Heart rate | >95 /min |
| SpO₂ on ambient/usual O₂ | <92% or >3% drop from baseline |
| CRP | >10 mg/L |
3. Persistent COPD-related dyspnea despite maintenance therapy — breathlessness or exercise limitation.
Path 2(a) is most patients — an ED visit or prednisone burst in the last year. Path 2(b) needs vitals + CRP during an exacerbation — build it at the time of the event, not reconstructed. VAS 0 = not short of breath, 10 = worst ever.
Large volume systems and humidification
Large volume nebulizer (A7007/A7017), compressor (E0565/E0572), and water/saline (A4217/A7018) are covered to deliver humidity for thick tenacious secretions with cystic fibrosis, bronchiectasis, tracheostomy, or tracheobronchial stent. Combo code E0585 = all three together (heavy-duty compressor + durable bottle nebulizer + immersion heater E1372) at the same time; otherwise billed separately.
Pentamidine, and the two pulmonary hypertension drugs
Pentamidine — filtered nebulizer
E0565/E0572 + filtered nebulizer A7006 for HIV, pneumocystosis, or transplant complications. Standard kit will not do.
Treprostinil J7686 — E0574
Small volume ultrasonic E0574 only for treprostinil in PH; with any other solution it denies. Requires PDAC verification + Product Classification List for DOS ≥4/1/2011.
Iloprost Q4074 — K0730
Controlled dose system K0730 only for iloprost. Iloprost requires same 3 criteria as treprostinil but interstitial lung disease does not open an extra pathway.
Treprostinil criteria: PAH not secondary to left-heart/venous or respiratory disorders (except ILD exception); primary or secondary to connective tissue/HIV/cirrhosis/anorexigens/congenital shunts + progression despite maximal treatment + mPAP >25 rest or >30 exertion + severe dyspnea/fatigability/angina/syncope + calcium channel blockers tried/ruled out. ILD pathway: HRCT ILD + mPAP ≥25 + PCWP/LVEDP ≤15 + PVR ≥3 WU + symptoms.
Accessories and how often they are replaced
Separately payable only in the combinations the policy allows:
What does not qualify
Denied as not reasonable & necessary
- None of the drugs covered → equipment + supplies denied
- Compounded solutions (including J7699)
- Above monthly maximums; duplicate short- or long-acting beta-agonists
- Ipratropium with revefenacin; loose drug with J7620
- Separate saline with unit dose; E0575 large volume ultrasonic
- E0574/K0730 with wrong drug; ensifentrine without dual/triple therapy
Non-covered (no benefit)
- Prefilled large volume A7008 (convenience)
- Cleaning kits/concentrates; room humidification
- Aztreonam lysine / amikacin liposome system + drugs — A9270 (not DME; may be Part D)
- MDI/DPI J3535 (Part D); disposable-major-component A9270
Which equipment the patient gets
Keeping coverage in place
What happens after we deliver
- Equipment + drugs billed together — same diagnosis on both; they fail together — we track the prescription.
- Repairs: Not separately reimbursed inside capped rental/warranty; on owned equipment, repairs to keep serviceable are covered — no new order, but record must show still reasonable & necessary. Cleaning kits non-covered.
- Discarded drug: Use formulations/sizes that minimize waste; JW for discarded remainder of single-use vial + JZ if nothing discarded; multi-use vials not eligible — our billing, but worth revisiting vial size if dose wastes most of it.
- SNF / travel / supplier change: SNF is not home — suspend shipments; compressor travels — time refills to travel; changing suppliers/MA→Medicare is a new initial claim with proof of delivery even for a compressor already in the home.
Referral checklist
Fax to (800) 438-2048 or call (800) 977-3002
- Note names the drug + condition and condition matches covered pair for that drug
- Diagnosis code included — on every claim
- Dose + frequency documented — monthly quantity calculable; checked against maximums + rescue ceilings
- No duplicate: not two short-acting, not two long-acting, not ipratropium with revefenacin, not loose drug with J7620
- For ensifentrine: maintenance therapy confirmed + exacerbation history or persistent dyspnea
- For large volume: CF / bronchiectasis / trach / stent documented
- SWO signed — no stamp; covers equipment + drug with quantity per time
Sources: LCD L33370 — Nebulizers; Policy Article A52466; Standard Documentation Requirements A55426. Last reviewed August 17, 2026.
Phone (800) 977-3002 · Fax (800) 438-2048 · Hours Mon–Thu 8:00–5:00, Fri 7:00–4:00 Pacific · 24/7 oxygen supportCall us